Literature DB >> 7763091

Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.

H Ihn1, S Sato, M Fujimoto, K Kikuchi, K Takehara.   

Abstract

Localized scleroderma has been reported to be accompanied by immunological abnormalities related to B cells, but little is known about T-cell activation in this disease. In this study, serum levels of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-6 (IL-6), which are known to be released by activated T cells, were determined using a sensitive enzyme-linked immunosorbent assay in 48 patients with localized scleroderma and 20 with systemic sclerosis, and in 20 healthy control subjects. IL-2, IL-4 and IL-6 were detected in serum from patients with localized scleroderma but not in that from healthy controls. The presence of antihistone antibodies correlated significantly with elevated IL-4 and IL-6 levels. Decreased serum levels of IL-2, IL-4 and IL-6 paralleled improvement in cutaneous sclerosis. Frequent detection of these lymphokines in serum from patients with localized scleroderma reflects T-cell activation in this disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7763091     DOI: 10.1007/BF01262331

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  40 in total

1.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

2.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

Authors:  D Degiannis; J R Seibold; M Czarnecki; J Raskova; K Raska
Journal:  Arthritis Rheum       Date:  1990-03

3.  Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T cells?

Authors:  H Umehara; S Kumagai; H Ishida; T Suginoshita; M Maeda; H Imura
Journal:  Arthritis Rheum       Date:  1988-03

Review 4.  The cutaneous collagenoses.

Authors:  R J Reed; W H Clark; M C Mihm
Journal:  Hum Pathol       Date:  1973-06       Impact factor: 3.466

Review 5.  Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells.

Authors:  T Yokota; N Arai; J de Vries; H Spits; J Banchereau; A Zlotnik; D Rennick; M Howard; Y Takebe; S Miyatake
Journal:  Immunol Rev       Date:  1988-02       Impact factor: 12.988

6.  Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.

Authors:  G Famularo; A Procopio; R Giacomelli; C Danese; S Sacchetti; M A Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.

Authors:  P J Clements; J B Peter; M S Agopian; N S Telian; D E Furst
Journal:  J Rheumatol       Date:  1990-07       Impact factor: 4.666

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.

Authors:  C A Feghali; K L Bost; D W Boulware; L S Levy
Journal:  J Rheumatol       Date:  1992-08       Impact factor: 4.666

10.  Antinuclear antibodies in the relatives of patients with systemic sclerosis.

Authors:  K Takehara; Y Moroi; Y Ishibashi
Journal:  Br J Dermatol       Date:  1985-01       Impact factor: 9.302

View more
  25 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

2.  Elevated soluble CD23 levels in the sera from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

3.  Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study.

Authors:  Kathryn S Torok; Thaschawee Arkachaisri
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

4.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis.

Authors:  C Mavalia; C Scaletti; P Romagnani; A M Carossino; A Pignone; L Emmi; C Pupilli; G Pizzolo; E Maggi; S Romagnani
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

Review 5.  Cytokine profiles in localized scleroderma and relationship to clinical features.

Authors:  Katherine Kurzinski; Kathryn S Torok
Journal:  Cytokine       Date:  2011-05-04       Impact factor: 3.861

6.  Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Authors:  Steven O'Reilly; Marzena Ciechomska; Rachel Cant; Jacob M van Laar
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

7.  Soluble CD4 and CD8 in serum from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

8.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

Review 9.  Novel role of long non-coding RNAs in autoimmune cutaneous disease.

Authors:  Anastasiya Muntyanu; Michelle Le; Zainab Ridha; Elizabeth O'Brien; Ivan V Litvinov; Philippe Lefrançois; Elena Netchiporouk
Journal:  J Cell Commun Signal       Date:  2021-08-03       Impact factor: 5.782

10.  Altered adhesion molecules expression on peripheral blood mononuclear cells from patients with systemic sclerosis and clinical correlations.

Authors:  Heloisa Helena Braga Sawaya; Romy Beatriz Christmann de Souza; Solange Carrasco; Claudia Goldenstein-Schainberg
Journal:  Clin Rheumatol       Date:  2009-02-19       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.